GI cancer resection OK with mild cirrhotic liver dysfunction

July 10, 2012
GI cancer resection OK with mild cirrhotic liver dysfunction
For patients with cirrhosis, resection of gastrointestinal malignancies correlates with poor early postoperative outcomes, with severity of liver disease being the primary determinant of postoperative mortality, according to a study published in the July issue of Cancer.

(HealthDay) -- For patients with cirrhosis, resection of gastrointestinal (GI) malignancies correlates with poor early postoperative outcomes, with severity of liver disease being the primary determinant of postoperative mortality, according to a study published in the July issue of Cancer.

To examine early postoperative and transitional outcomes in cirrhotic patients undergoing GI , Avo Artinyan, M.D., from the Michael E. DeBakey VA Medical Center in Houston, and colleagues analyzed data from the National Inpatient Sample Database (2005 to 2008) and identified 106,729 patients who underwent resection for GI , of whom 1,479 (1.4 percent) were diagnosed with cirrhosis.

The researchers found that patients with cirrhosis had a significantly increased risk of in-hospital mortality (8.9 versus 2.8 percent), longer length of stay (11.5 ± 0.26 versus 10.0 ± 0.03 days), and higher rate of discharge to long-term care facilities (19.0 versus 15.7 percent). Patients with moderate-to-severe liver dysfunction had the highest mortality (21.5 versus 6.5 percent). Cirrhosis was an independent predictor of in-hospital mortality and non-home discharge (odds ratios [ORs], 3.0 and 1.7, respectively), in multivariate analysis. Moderate-to-severe liver dysfunction was the only independent predictor of in-hospital mortality for patients with cirrhosis (OR, 4.03).

"Resection of GI malignancy in cirrhotics is associated with poor early postoperative and transitional outcomes, with severity of being the primary determinant of postoperative mortality," the authors write. "These data suggest that GI cancer operations can be performed safely in well-selected with mild liver dysfunction."

Explore further: Better short-Term outcomes for private prostatectomies

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Better short-Term outcomes for private prostatectomies

March 30, 2012
(HealthDay) -- For men undergoing radical prostatectomies (RPs), private health insurance coverage is linked with fewer complications, less in-hospital recovery time, and decreased mortality, compared to public coverage, ...

Liver stiffness predicts liver failure, cancer and mortality in cirrhotic patients

July 10, 2012
Researchers from Spain established that liver stiffness, measured by transient elastography (TE), is an independent predictor of liver failure, hepatocellular carcinoma (HCC), and mortality in cirrhotic patients coinfected ...

Liver cancer incidence lower in patients with nonalcoholic fatty liver disease than hepatitis C

September 27, 2011
Patients with non-alcoholic fatty liver disease (NAFLD) with advanced fibrosis or cirrhosis have a lower incidence of liver-related complications and hepatocellular carcinoma (HCC) than patients infected with hepatitis C ...

The economic cost of advanced liver disease

November 7, 2011
Health care costs for hepatitis C patients with end-stage liver disease are nearly 2.5 times higher than those in the early stages, according to a Henry Ford Hospital study.

Recommended for you

Researchers compose guidelines for handling CAR T cell side effects

September 19, 2017
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University ...

Altitude training for cancer-fighting cells

September 18, 2017
Mountain climbers and endurance athletes are not the only ones to benefit from altitude training - that is, learning to perform well under low-oxygen conditions. It turns out that cancer-fighting cells of the immune system ...

Metabolism can be used to subtype hepatoblastoma tumors

September 18, 2017
Looking at cell metabolism instead of histology, EPFL scientists have identified new biomarkers that could help more accurately classify the two main subtypes of hepatoblastoma, a children liver cancer.

A new paradigm for treating transcription factor-driven cancers

September 18, 2017
In the current issue of Proceedings of the National Academy of Sciences, researchers from Nationwide Children's Hospital describe a new paradigm for treating transcription factor-driven cancers. The study focuses on Ewing ...

Scientists find bacteria in pancreatic tumors that metabolize a common drug

September 15, 2017
To the reasons that chemotherapy sometimes does not work, we can now add one more: bacteria. In a study published today in Science, researchers describe findings that certain bacteria can be found inside human pancreatic ...

New technologies combined to identify specific DNA defect underlying a type of cancer

September 15, 2017
(Medical Xpress)—A team of researchers from the Netherlands and the U.K. has developed a technique for studying inherited types of cancers using two relatively new technologies—organoid development and CRISPR/Cas9. In ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.